Biopolym. Cell. 2015; 31(4):264-271.
The effect of antiviral substance 6-(2-morpholin-4-yl-ethyl)-6H-indolo [2,3-b]quinoxaline upon biomarkers of inflammation
1Antonovych G. V., 1Zholobak N. M., 2Shibinska M. O., 1Spivak M. Ya.
  1. D. K. Zabolotny Institute of Microbiology and Virology, NAS of Ukraine
    154, Academika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. O. V. Bogatsky's Physico-chemical Institute, NAS of Ukraine
    86, Lustdorfskaya dor., Odessa, Ukraine, 65080


Aim. To investigate changes in pro-inflammatory status of laboratory rats after introduction of antiviral substances with interferon-inducing action: 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline and tilorone. Methods. MCP-1 content, blood leukocyte counts and functional activity of phagocytes were measures using flow cytometry techniques. Complement content was determined in microtest based upon hemolysis of sensitized erythrocytes. Results. Both oral and intraperitoneal applications of the substances were characterized by an elevation in monocytic counts, potentiated metabolic reserve of phagocytic cells, increased MCP-1 and complement content in serum. In contrast to tilorone, after introduction of 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline substantial raise in circulating neutrophil counts and their phagocytic activity was not determined, while MCP-1 and complement responses were significantly lower compared to reference substance. Conclusion. Although both substances are IFN-inducers with pluripotent immunostimulatory action, the tested derivative was characterized by a less pronounced elevation of complement activity, MCP-1 content and neutrophil counts. This implies that application of 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline can strengthen innate antiviral resistance with minimized risks of potential autoimmunological adverse effects.
Keywords: 6H-indolo[2;3-b]quinoxalines, inflammation, interferon, MCP-1, complement


[1] Shibinskaya MO, Lyakhov SA, Mazepa AV, Andronati SA, Turov AV, Zholobak NM, Spivak NY. Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines. Eur J Med Chem. 2010;45(3):1237-43.
[2] Antonovych GV, Zholobak NM, Lyakhov SA, Shibinska MO, Andronati SA, Spivak MY. Dose-dependent IFN-stimulating and immunomodulating properties of 6H-indolo[2,3-B] qu­i­noxaline derivatives. Mikrobiol Z. 2012;74(4):79–86.
[3] Inglis JE, Radziwon KA, Maniero GD. The serum complement system: a simplified laboratory exercise to measure the activity of an important component of the immune system. Adv Physiol Educ. 2008;32(4):317-21.
[4] Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010;411(21-22):1570-9.
[5] Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol. 1995;25(1):64-8.
[6] Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-26.
[7] Suresh M, Molina H, Salvato MS, Mastellos D, Lambris JD, Sandor M. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol. 2003;170(2):788-94.
[8] Kim AH, Dimitriou ID, Holland MC, Mastellos D, Mueller YM, Altman JD, Lambris JD, Katsikis PD. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol. 2004;173(4):2524-9.
[9] Qing X, Koo GC, Salmon JE. Complement regulates conventional DC-mediated NK-cell activation by inducing TGF-β1 in Gr-1+ myeloid cells. Eur J Immunol. 2012;42(7):1723-34.
[10] Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol. 2000;74:61-88.
[11] Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chu­dnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612–6.
[12] Goldstein IM, Roos D, Kaplan HB, Weissmann G. Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest. 1975;56(5):1155-63.
[13] Goldstein IM, Feit F, Weissmann G. Enhancement of nitroblue tetrazolium dye reduction by leukocytes exposed to a component of complement in the absence of phagocytosis. J Immunol. 1975;114(1 Pt 2):516-8.
[14] Wilhelmsson LM, Kingi N, Bergman J. Interactions of antiviral indolo[2,3-b]quinoxaline derivatives with DNA. J Med Chem. 2008;51(24):7744-50.
[15] The biology and pathology of innate immunity mechanisms. Eds. Keisari Y, Ofek I. Advances in experimental medicine and biology, Vol 479. Kluwer Academic, 2002. 242 p.
[16] Strauss-Ayali D, Conrad SM, Mosser DM. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol. 2007;82(2):244-52.
[17] Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2014;2(1):1.